Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, has shown rapid action and gastric acid inhibition. In this study, we evaluated the efficacy of a tegoprazan-based, nonbismuth-containing quadruple (concomitant) therapy for the primary eradication of Helicobacter pylori. Methods: We conducted a prospective, single-arm, single-center, primitive study to verify the efficacy of a 10-day tegoprazan- based (50-mg dose) concomitant therapy, including amoxicillin (1,000-mg dose), clarithromycin (CLA; 500-mg dose), and metronidazole (MET; 500-mg dose) twice daily as a first-line treatment for H. pylori eradication. Results: We tested consecutive cultures for antibiotic susceptibility and minimum inhibitory concentrations. We enrolled 84 participants; 79 (94.0%) completed first-line therapy. The overall intention-to-treat and per-protocol eradication rates were 90.5% (95% confidence interval [CI], 82.1−95.8) and 96.2% (95% CI, 83.4–97.6), respectively. Of the 73 participants evaluated for antibiotic resistance, 19 (26.0%), 32 (42.5%), and 8 (11.0%) exhibited CLA, MET, and CLA and MET dual resistance, respectively. Of these, 39 participants (66.1%) exhibited successful eradication after the therapeutic regimen despite antibiotic resistance. Conclusions: The 10-day tegoprazan-based concomitant therapy may be an effective first-line treatment for eradicating H. pylori.
Abstract
Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, has shown rapid action and gastric acid inhibition. In this study, we evaluated the efficacy of a tegoprazan-based, nonbismuth-containing quadruple (concomitant) therapy for the primary eradication of Helicobacter pylori. Methods: We conducted a prospective, single-arm, single-center, primitive study to verify the efficacy of a 10-day tegoprazan- based (50-mg dose) concomitant therapy, including amoxicillin (1,000-mg dose), clarithromycin (CLA; 500-mg dose), and metronidazole (MET; 500-mg dose) twice daily as a first-line treatment for H. pylori eradication. Results: We tested consecutive cultures for antibiotic susceptibility and minimum inhibitory concentrations. We enrolled 84 participants; 79 (94.0%) completed first-line therapy. The overall intention-to-treat and per-protocol eradication rates were 90.5% (95% confidence interval [CI], 82.1−95.8) and 96.2% (95% CI, 83.4–97.6), respectively. Of the 73 participants evaluated for antibiotic resistance, 19 (26.0%), 32 (42.5%), and 8 (11.0%) exhibited CLA, MET, and CLA and MET dual resistance, respectively. Of these, 39 participants (66.1%) exhibited successful eradication after the therapeutic regimen despite antibiotic resistance. Conclusions: The 10-day tegoprazan-based concomitant therapy may be an effective first-line treatment for eradicating H. pylori.
참고문헌 (40)
- Malfertheiner P, "Management of Helicobacter pylori infection-the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
- Boyanova L, "Multidrug resistance in Helicobacter pylori : current state and future directions", Expert Rev Clin Pharmacol, 12, pp.909~915 (2019)
- Gatta L, "Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection : lessons from a 5-year study on a large number of strains", Aliment Pharmacol Ther, 47, pp.1261~1269 (2018)
- Lee JH, "Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: a prospective multicenter study", Helicobacter, 24, pp.e12592~ (2019)
- Chey WD, "ACG clinical guideline : treatment of Helicobacter pylori infection", Am J Gastroenterol, 112, pp.212~239 (2017)
- Fallone CA, "Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics", Gastroenterology, 157, pp.44~53 (2019)
- Muñoz N, "Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review", Gastroenterol Hepatol, 41, pp.654~662 (2018)
- Liou JM, "Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial", Lancet, 388, pp.2355~2365 (2016)
- Molina-Infante J, "Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study", Aliment Pharmacol Ther, 41, pp.581~589 (2015)
- Molina-Infante J, "Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance", Gastroenterology, 145, pp.121~128 (2013)
- Beom Jin Kim, "Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea", Gut and Liver, 13(5), pp.531~540 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Fallone CA, "The Toronto consensus for the treatment of Helicobacter pylori infection in adults", Gastroenterology, 151, pp.51~69 (2016)
- Scott DR, "The role of acid inhibition in Helicobacter pylori eradication", F1000Res, 5 (2016)
- Murakami K, "Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication : a phase III, randomised, double-blind study", Gut, 65, pp.1439~1446 (2016)
- Kiyotoki S, "Efficacy of vonoprazan for Helicobacter pylori eradication", Intern Med, 59, pp.153~161 (2020)
- Jung YS, "Systematic review with meta-analysis : the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication", Aliment Pharmacol Ther, 46, pp.106~114 (2017)
- -N-methylmethanamine monofumarate(TAK-438), "J Pharmacol Exp Ther", 2011, 412~420
- Rokkas T, "Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection : a network meta-analysis", Gastroenterology, 161, pp.495~507 (2021)
- Lyu QJ, "Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication : a meta-analysis of randomized clinical trials", Biomed Res Int, 2019, pp.9781212~ (2019)
- Takahashi N, "Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility", J Pharmacol Exp Ther, 364, pp.275~286 (2018)
- Han S, "Randomised clinical trial : safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan(CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects", Aliment Pharmacol Ther, 50, pp.751~759 (2019)
- Kagami T, "Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype", Aliment Pharmacol Ther, 43, pp.1048~1059 (2016)
- Cho YK, "Randomised clinical trial : tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer", Aliment Pharmacol Ther, 52, pp.789~797 (2020)
- Lee KJ, "Randomised phase 3 trial : tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis", Aliment Pharmacol Ther, 49, pp.864~872 (2019)
- Park CG, "Validation of loop-mediated isothermal amplification to detect Helicobacter pylori and 23S rRNA mutations : a prospective, observational clinical cohort study", J Clin Lab Anal, 35, pp.e23563~ (2021)
- Kwon YH, "Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure : a single-center prospective pilot study", Helicobacter, 24, pp.e12585~ (2019)
- "Clinical breakpoints - breakpoints and guidance, version 13.0" (2023)[URL]
- Hwang JY, "Clarithromycin and metronidazole resistance is the main cause of failure in ultimate Helicobacter pylori eradication", Dig Dis, 39, pp.451~461 (2021)
- Roebruck P, "Comparison of tests and sample size formulae for proving therapeutic equivalence based on the difference of binomial probabilities", Stat Med, 14, pp.1583~1594 (1995)
- Gisbert JP, "Update on non-bismuth quadruple(concomitant)therapy for eradication of Helicobacter pylori", Clin Exp Gastroenterol, 5, pp.23~34 (2012)
- Jung Hye-Kyung, "Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020", Gut and Liver, 15(2), pp.168~195 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Han S, "Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan", Clin Ther, 43, pp.1371~1380 (2021)
- Kim DK, "Effects of tegoprazan, a novel potassium-competitive acid blocker, on rat models of gastric acid-related disease", J Pharmacol Exp Ther, 369, pp.318~327 (2019)
- Abdel-Aziz Y, "Review article : potassium-competitive acid blockers for the treatment of acid-related disorders", Aliment Pharmacol Ther, 53, pp.794~809 (2021)
- Kim SH, "Randomised clinical trial : comparison of tegoprazan and placebo in non-erosive reflux disease", Aliment Pharmacol Ther, 54, pp.402~411 (2021)
- Yang E, "Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole", Br J Clin Pharmacol, 88, pp.3288~3296 (2022)
- Iwahi T, "Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori", Antimicrob Agents Chemother, 35, pp.490~496 (1991)
- Lee Jung Won, "Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori", Gut and Liver, 15(1), pp.53~60 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Ghim JL, "Pharmacokinetics and pharmacodynamics of tegoprazan coadministered with amoxicillin and clarithromycin in healthy subjects", J Clin Pharmacol, 61, pp.913~922 (2021)
- Choi Yoon Jin, "Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial", Gut and Liver, 16(4), pp.535~546 (2022), 거트앤리버 소화기연관학회협의회[DOI]